Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crispr Therapeutics Ag (NQ: CRSP )

42.94 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 145
Open 42.94
Bid (Size) 42.78 (1)
Ask (Size) 46.00 (1)
Prev. Close 42.94
Today's Range 42.94 - 42.94
52wk Range 38.94 - 66.31
Shares Outstanding 78,935,098
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biotechnology Breakthroughs: 3 Biotech Stocks That Could Make Early Investors Rich
Are you looking to invest in biotechnology breakthroughs? Here are three biotech stocks that could make early investors rich. 
Via InvestorPlace
Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead?
The Internet's most famous innovation-focused investor is excited about this company's innovative approach to editing the human genome. 
Via The Motley Fool

Performance

YTD
+4.73%
+4.73%
1 Month
-14.56%
-14.56%
3 Month
-24.39%
-24.39%
6 Month
-1.76%
-1.76%
1 Year
-31.95%
-31.95%

More News

Read More
2 Top Biotech Stocks to Buy in October
Via The Motley Fool
Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics
Via The Motley Fool
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
Via The Motley Fool
2 Bargain Growth Stocks to Buy Hand Over Fist
Via The Motley Fool
3 Cathie Wood Stocks Set to Explode Higher
Via InvestorPlace
Futurescape: Betting Big on These 3 Next-Gen Tech Stocks
Via InvestorPlace
3 No-Brainer Growth Stocks to Buy in October
Via The Motley Fool
Editas Medicine Is Beyond Skepticism, Analyst Has Confidence In Sickle Cell Therapy, Upgrades Stock
Via Benzinga
Why Editas Medicine Stock Is Soaring Today
Via The Motley Fool
If I Could Only Buy 3 Stocks in 2023, I'd Pick These
Via The Motley Fool
Crispr Therapeutics, And CRISPR Gene-Editing, Face Their Make-Or-Break Moment
Via Investor's Business Daily
Exposures Product Safety
Don’t Miss the Boom: 3 Pharma Stocks Set to Explode Higher
Via InvestorPlace
From Dust to Diamonds: 7 Undervalued Stocks With Sparkling Prospects
Via InvestorPlace
Are Gene Therapy Stocks The Market's Next Big Winners?
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
2 Cathie Wood Stocks to Buy Hand Over Fist Right Now
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023
Via Benzinga
$10,000 Invested in These Growth Stocks Could Make You a Fortune Over the Next 10 Years
Via The Motley Fool
Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio
Via The Motley Fool
Flee to Healthcare Stocks if Recession Rears its Head?
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Where Will CRISPR Therapeutics Be in 5 Years?
Via The Motley Fool
1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know
Via The Motley Fool
2 Top Trends to Invest $500 In Right Now
Via The Motley Fool
Looking for Growth? These Companies' Revenue May Skyrocket
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.